Last reviewed · How we verify

NCT05290701: EPES

Evaluating Prenatal Exome Sequencing Study

Active, enrolled Last updated 6 March 2025
What this trial tests

trial in Congenital Anomalies in 235 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
21 February 2022
Primary endpoint
1 October 2025
1 October 2026

Quick facts

Lead sponsorLeiden University Medical Center
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment235
Start date21 February 2022
Primary completion1 October 2025
Estimated completion1 October 2026
Sites1 location across Netherlands

Conditions studied

Sponsor

Leiden University Medical Center

Who can join

18 and older, any sex, with Congenital Anomalies or Mendelian Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the impact of the various outcomes of pES (definitive diagnosis, probable diagnosis and IF) on clinical decision making and on parental psychological wellbeing, compared between different analysis strategies to investigate the clinical utility, defined as the balance between potential harms and benefits.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Congenital Anomalies

Currently open trials in the same condition.

Other Leiden University Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05290701.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing